Quarterly ResultMay 12, 2026, 04:19 PM
MaxCyte Q1 Revenue $9.7M, Net Loss $4.8M; Authorizes $10M Buyback
AI Summary
MaxCyte, Inc. announced its first quarter 2026 financial results, reporting total revenue of $9.7 million, a 7% decrease year-over-year, with core business revenue declining by 25% to $6.2 million. However, SPL Program-related revenue increased by 50% to $3.4 million, and the net loss improved to $4.8 million from $10.3 million in the prior year. The company reiterated its full-year 2026 revenue guidance of $30-32 million and authorized a $10 million share repurchase program, reflecting confidence in its strategy and long-term value.
Key Highlights
- MaxCyte's Board authorized a $10 million share repurchase program within a one-year period.
- Total revenue for Q1 2026 was $9.7 million, a 7% decrease compared to $10.4 million in Q1 2025.
- Core business revenue for Q1 2026 was $6.2 million, a 25% decrease from $8.2 million in Q1 2025.
- Strategic Platform License (SPL) Program-related revenue was $3.4 million, a 50% increase from $2.1 million in Q1 2025.
- Net loss for Q1 2026 improved to $4.8 million from a net loss of $10.3 million in Q1 2025.
- Gross profit for Q1 2026 was $8.1 million, representing an 84% gross margin.
- The company reiterated its full-year 2026 revenue guidance of $30 million to $32 million.
- Total cash, cash equivalents, and investments were $147.7 million as of March 31, 2026.